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1. Abstract 
Aims: Pericardial effusion (PE) is a common finding in cardiac patients with chronic heart 
failure. The prognostic relevance of a small, haemodynamically non-compromising PE in 
such patients, however, remains to be determined. 
Methods and results: All patients referred to our heart failure clinic and having a baseline 
echocardiography and follow-up clinical visits were included. Patients with a 
haemodynamically relevant PE, acute myo-/pericarditis, systemic sclerosis, rheumatoid 
arthritis, heart transplantation, heart surgery within the last 6 months, or malignancies 
within the last 3 years were excluded. Patients with or without a haemodynamically 
irrelevant PE were compared regarding all-cause mortality as the primary and 
cardiovascular death or need for heart transplantation as secondary outcomes. A total of 
897 patients (824 patients in the control vs. 73 patients in the PE group) were included. In 
the PE group, left ventricular ejection fraction (LVEF) was lower [31%, interquartile range 
(IQR): 18.0-45.0] than in controls (34%, IQR: 25.0-47.0; p=0.04), while the end-systolic 
diameters of the left ventricle (LV) and the left atrium (LA) were larger (p=0.01 and 
p=0.001, respectively). Similarly, in patients with PE, the right ventricle (RV) systolic 
function was lower (p<0.005 for both the fractional area change and the tricuspid annulus 
movement), the dimensions of RV and right atrium (RA) were larger (p<0.05 for RV and 
p<0.01 for RA), and the degree of tricuspid regurgitation was higher (p<0.0001). 
Furthermore, in the PE group, the heart rate was higher (p<0.001) and the leucocyte count 
as well as CRP values were increased (p=0.004 and p<0.0001, respectively); beta-blocker 
use was less frequent (p=0.04), while spironolactone use was more frequent (p=0.03). The 
overall survival was reduced in the PE group compared with controls (p=0.02). Patients 
with PE were more likely to suffer cardiovascular death (1-year estimated event-free 
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survival: 86 ± 5 vs. 95 ± 1%; p=0.01) and to require heart transplantation (1-year estimated 
event-free survival: 88 ± 4 vs. 95 ± 1%; p=0.009). A multivariate Cox proportional hazard 
model revealed the following independent predictors of mortality: (a) PE [p=0.04, hazard 
ratio (HR): 1.95, 95% confidence interval (CI): 1.0-3.7], (b) age (p=0.04, HR: 1.02, 95% CI: 
1.0-1.04) and (c) LVEF < 35% (p=0.03, HR: 1.7, 95% CI: 1.1-2.8). 
Conclusion: In chronic heart failure, even minor PEs are associated with an increased 
risk of all-cause mortality, cardiac death, and need for transplantation.  
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2. Introduction 
In patients with chronic heart failure, haemodynamically irrelevant PE is a common (12-
20%) finding during routine echocardiography examinations.1-3 Usually, such findings do 
not influence clinical decision-making as long as the PE is not considered 
haemodynamically compromising. While in some patients, pericardial fluid accumulation 
can be attributed to an underlying systemic or local inflammatory process4 such as cancer5 
or myo-/pericarditis6 or might occur after surgery7, the mechanism of PE and its prognostic 
value in heart failure remain elusive. Importantly, in patients with severe pulmonary 
hypertension, several studies have revealed a strong association of a small PE with 
adverse outcome.8,9 The mechanism of increased pericardial fluid production is 
incompletely understood in that patient population.10 
Thus, it was the aim of the present study to evaluate the prognostic relevance of 
haemodynamically insignificant PE in a heart failure population and to identify potential 
mechanisms for pericardial fluid accumulation in these patients. 
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3. Methods 
3.1. Patient population and baseline characteristics 
We searched our echo-laboratory and heart failure clinic database and identified all the 
patients who had undergone a baseline echocardiography from 1990 until 2010 and had a 
baseline and at least one follow-up visit in our heart failure clinic. The exclusion criteria 
were heart or lung transplantation before the baseline echocardiography, cardiac surgery 
within 6 months prior to baseline, myocardial infarction or suspected acute peri-
/myocarditis within the last 3 months, rheumatoid arthritis, systemic sclerosis, systemic 
lupus, patients receiving chemotherapy due to cancer within the last 6 months, or patients 
with known metastatic cancer. Patients presenting with a haemodynamically relevant PE at 
baseline echocardiography were excluded as well.  
Data on age, gender, body mass index, underlying heart rhythm, underlying heart disease 
(ischaemic vs. non-ischaemic), O2 uptake during exercise, New York Heart Failure (NYHA) 
functional class, ICD/cardiac resynchronization therapy (CRT) implantation, and 
medication were retrieved from database and patient records.  
3.2. Study groups and outcome measures 
Patients presenting with a haemodynamically irrelevant PE on echocardiography were 
allocated to the PE group and the date of this echocardiogram represented the baseline. 
Patients with no signs of PE were included in the control group and the first available 
echocardiography represented the baseline. The primary outcome measure was all-cause 
mortality. Secondary outcome measures were cardiovascular mortality and need for heart 
transplantation. Inflammatory markers (leucocyte count and C reactive protein) and right 
ventricular function were evaluated as well.  
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3.3. Echocardiography 
All echocardiograms were analyzed by two experienced physicians. Echocardiographic 
parameters (grading of mitral and tricuspid regurgitation, tricuspid annulus movement 
(TAM), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter 
(LVEDD), left ventricular end-systolic diameter (LVESD), atrial and right ventricular 
dimensions) were analyzed according to current guidelines of the European Society of 
Cardiology.11-15 A PE was considered haemodynamically relevant if at least one of the 
following criteria was present: (i) paradoxical movement of the interventricular septum with 
respiration, (ii) presence of a collapsing right ventricle during diastole, and (iii) typical 
ventricular E-wave velocity changes with inspiration.16  
3.4. Haemodynamic parameters 
Patients with a PE who underwent left and right heart catheterization at baseline were 
matched to patients in the control group with data available on left and right heart 
catheterization. Patients were matched 1:1 with regard to age, gender, NYHA functional 
class, ischaemic vs. non-ischaemic cardiomyopathy, diuretic, angiotensin converting 
enzyme (ACE) inhibitor and beta-blocker treatment, and LVEF. 
The left ventricular end-diastolic pressure, right ventricular end-diastolic pressure, wedge 
pressure as well as the mean pulmonary arterial pressure were investigated. The 
transpulmonary gradient was calculated as mean pulmonary artery pressure – mean 
wedge pressure. 
3.5. Laboratory parameters 
Blood samples were taken at baseline. The leucocyte count was recorded. C-reactive 
protein and NT-proBNP levels were analyzed using the cobas® analyzer (Roche 
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Diagnostics, Basel, Switzerland) at the Institute of Clinical Chemistry of the University 
Hospital Zurich.  
3.6. Follow-up examination 
All patients had at least one follow-up visit in the heart failure clinic. Usually, patients were 
examined every 6 months by a heart failure specialist with a physical examination and 
laboratory analysis including  blood count, CRP, proBNP, and creatinine. Patients with 
recently detected cancer were identified. If a patient died during follow-up, the results of an 
autopsy or the latest medical reports were analysed to identify the cause of death. 
In patients with PE at baseline, all follow-up echocardiograms were analyzed to document 
the evolution of the PE, and the time to resolution of the PE from a baseline was 
determined. In patients with PE at baseline, chest X-rays at baseline were examined for 
concomitant pleural effusions and noted as uni- or bilateral.    
3.7. Statistics 
All statistical analyses were performed using SPSS 20.0 (IBM Corporation, 1 New Orchard 
Road Armonk, New York 10504-1722, United States). Continuous variables are presented 
as the median and interquartile range (IQR) (25–75 percentile). The  and Mann-Whitney 
U test were used as appropriate. For survival analysis, a Kaplan-Meier curve was 
computed and a log rank p-value was calculated. A Cox proportional hazard model was 
applied for the primary outcome measure, corrected for age, gender, heart rate, heart 
rhythm, LVEF<35%, body mass index, underlying heart disease, beta-blocker and 
spironolactone therapy.  
A sensitivity analysis with a Cox proportional hazard model was performed for mortality, 
also adjusting for NT-proBNP and CRP values (NT-proBNP and CRP were both obtained 
in 181 patients only). A two-sided p-value of <0.05 was considered significant. 
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4. Results 
4.1. Patient population and baseline characteristics 
A total of 1213 patients were retrieved from the database. One hundred patients having 
undergone heart or lung transplantation before the baseline echocardiography as well as 
147 patients after recent cardiac surgery were excluded. Furthermore, 49 patients having 
sustained a myocardial infarction within 3 months before the baseline echocardiography, 6 
patients with acute peri-/myocarditis, and 11 patients with uncontrolled cancer were also 
excluded. Three patients had a haemodynamically significant PE. Among the 897 patients 
finally included, 73 patients exhibited a haemodynamically irrelevant PE.  
There was a borderline significant difference between the PE and the control group with 
regard to age [53.4 years (IQR: 34.4-62.7) vs. 55.5 years (IQR: 45.9-64.5); p=0.05], but 
not with regard to male gender [53 patients (73%) vs. 675 patients (82%); p=0.06]. A body 
mass index was lower in the PE group [24.7 kg/m2 (IQR: 21.1-27.0) vs. 25.8 kg/m2 (IQR: 
23.4-29.2); p=0.004; Table 1]. 
The heart rate was higher in patients with PE (87/min, IQR: 76.0-98.0) than that in controls 
(76/min, IQR: 65.0-89.0; p<0.0001), use of beta-blockers was lower in patients with PE (33 
patients, 45%) than in controls (479 patients, 58%; p=0.04) and the number of patients 
with non-ischaemic cardiomyopathy was higher in the PE group (n=57, 78%) than in 
controls (n=502, 61%). 
Thirty-one (43%) patients with PE had a chest X-ray at baseline. In 20 (64%) patients, a 
concomitant pleural effusion was found and in most cases located bilaterally (n=11; 55%). 
4.2. Left ventricular and atrial parameters 
The left ventricular ejection fraction was lower [31% (IQR: 18.0-45.0) vs. 34% (IQR: 25.0-
47.0); p=0.04] and LVESD was larger in the PE (5.6 cm, IQR: 4.0-6.7) than the control 
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group (4.9 cm, IQR: 3.7-5.9; p=0.01). The left atrial end-systolic diameter was larger in the 
PE (5.0 cm, IQR: 4.4-5.8) than the control group (4.6 cm, IQR: 4.0-5.2; p=0.001). The 
severity of mitral regurgitation did not differ between the PE and the control group [Grade 2 
(IQR: 1-3) vs. Grade 2 (IQR: 1-2); p=0.67, Table 2]. 
4.3.  Right ventricular and atrial parameters 
The right ventricular diameter (four-chamber view, short axis) was increased [3.5 cm (IQR: 
2.9-4.0) vs. 3.2 cm (IQR: 2.7-3.6); p=0.02)] and the right ventricular systolic function was 
decreased in patients with PE compared to the control group: Right ventricular fractional 
area change (RV-fac) [median 33% (IQR: 19.0-42.0) vs. 39% (IQR: 33.0-49.0); p=0.002], 
tricuspid annulus movement [median 14.5 mm (IQR: 11.8-20.0) vs. 18.0 mm (IQR: 15.0-
21.0); p=0.003; Figure 1]. The right atrial end-systolic diameter was larger in the PE than 
the control group (p=0.001). Tricuspid regurgitation was more pronounced in the PE than 
the control group [Grade 2 (IQR: 1-2) vs. Grade 1 (IQR: 1-2); p<0.0001; Table 2]. 
4.4. Haemodynamic parameters 
In the patient population with PE, 29 patients (40%) had left and right heart catheterization 
at baseline. These patients were matched 1:1 to patients retrieved from the control group. 
No significant difference between the groups was detected with regard to age, gender, 
NYHA functional class, diuretic or ACE inhibitor or beta-blocker treatment, ischaemic vs. 
non-ischaemic cardiomyopathy, and LVEF.  
Patients with PE had a higher right ventricular end-diastolic pressure [8.5 mmHg (IQR: 6.0-
15.5) vs. 6.5 mmHg (IQR: 3.0-10.0); p=0.008] and mean pulmonary arterial pressure [32.0 
mmHg (IQR: 22.5-43) vs. 22.5 mmHg (IQR: 16.3-36); p=0.03], whereas the left ventricular 
end-diastolic pressure [22.5 mmHg (IQR: 18.3-30.8) vs. 20 mmHg (IQR: 13.3-26.3); 
p=0.27] and the wedge pressure [20 mmHg (IQR: 14.0-27.0) vs. 16 mmHg (IQR: 9.5-24.5); 
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p=0.14] did not differ between the study groups (Figure 2). The transpulmonary gradient 
was higher in the PE group compared with controls [12.0 mmHg (IQR: 6.5-18.5) vs. 7.0 
mmHg (IQR: 4.0-12.0); p=0.04]. 
4.5. Laboratory markers of cardiac function and inflammation 
NT-proBNP, CRP, and leucocyte values at baseline were available in 232, 344, and 589 
patients, respectively. The NT-proBNP value was significantly increased in the PE group 
compared with controls [2240 ng/L (IQR: 1085-5379) vs. 1214 ng/L (IQR: 411-2596); 
p=0.01].  
Laboratory markers of inflammation were significantly increased in the PE group compared 
with controls, i.e. the leucocyte count was higher [8.4 x 103/µL (IQR: 7.0-11.3) vs. 7.7 x 
103/µl (IQR: 6.1-9.1; p=0.004] as were the plasma levels of C-reactive protein [15.0 mg/L 
(IQR: 4.2-40.3) vs. 3.0 mg/L (IQR: 1.0-12.0; p<0.0001); Figure 3]. 
A Cox proportional hazard model (analysing n=181 patients) confirmed an independent 
association of PE (p=0.03; hazard ratio (HR): 3.2, 95% CI: 1.1-9.4) and NT-proBNP (per 
100 ng/L: p<0.0001, HR: 1.01, 95% CI: 1.007-1.02), but not CRP (per mg/L: p=0.47, HR: 
1.005, 95% CI: 0.99-1.02) with mortality. 
4.6. Echocardiographic follow-up 
Fifty-three (73%) patients in the PE group had an echocardiographic follow-up. The 
median follow-up period was 4.4 months (IQR: 1.8-14). Thirteen (25%) patients had 
persisting PE. Four patients (31%) with persisting PE died, while only 6 patients (15%) 
died in the group with resolved PE (1-year estimated event-free survival: 63.5 ± 15% vs. 
96.7 ± 3%; p=0.007). 
10 
 
4.7. Clinical follow-up 
The median follow-up time was 1.8 years (IQR: 0.3-5.5) in the PE group and 3.4 years 
(IQR: 1.1-7.1) in the control group. A total of 209 patients (23%) died with 159 patients 
(18%) dying from a cardiac cause, 11 patients (1%) from infection, and 14 patients (2%) 
from cancer. In 15 patients (2%) the cause of death remained unknown (Table 3). In 38 
patients (4%) a malignancy was diagnosed during the follow-up period. 
The overall survival was significantly reduced in patients with PE as compared with 
controls (Figure 4; p=0.02). A Cox proportional hazard model revealed an independent 
association of PE with death (Table 4; p=0.04). Patients in the PE group were more likely 
to die from a cardiac cause as compared with the control group (1-year estimated event-
free survival: 86 ± 5% vs. 95 ± 1%; p=0.01; Table 3). Heart transplantation was necessary 
in 77 (9%) patients. Patients with a PE were more likely to require transplantation when 
compared with the control group (1-year estimated event-free survival: 88 ± 4% vs. 95 ± 
1%; p=0.009; Table 3).  
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5. Discussion 
5.1. Main results 
This study demonstrates that in a chronic heart failure population the presence of a 
haemodynamically irrelevant PE is independently associated with a nearly two-fold hazard 
of death. Of note, a persistent PE at echocardiographic follow-up was associated with 
unfavourable outcome when compared with patients with resolved PE. Cardiovascular 
events were the main cause of death in these patients with as well as in those without PE; 
however, at 1 year, patients with PE had an increased risk to die from a cardiac cause 
compared with those without it, and they were more likely to require heart transplantation. 
In addition, patients with PE had a higher NT-proBNP level identifying a higher risk 
population for major adverse events.17,18 Consistent with these observations, patients with 
PE had a lower left and right ventricular ejection fraction, larger left and right atrial 
dimensions, and a worse NYHA functional class.  
While the exact underlying mechanisms, by which the PE might be associated with 
adverse outcome remains to be determined,19,20 the results of the present study suggest 
that congestion of venous blood or lymphatic fluid return to the right heart might have an 
impact on the evolution of PE of non-inflammatory origin. Furthermore, pulmonary 
pressure per se and/or regulatory mechanisms operative under these conditions seem to 
be of importance. Nevertheless, the mechanisms by which PE might be associated with 
adverse outcome remain speculative. In patients with severe pulmonary hypertension, an 
impaired right ventricular function and/or a PE are detected in 22 and 25%, respectively, 
and both are independently associated with a poor prognosis.21 Intriguingly, it has been 
shown previously that NT-proBNP reflects the right ventricular structure and function in 
patients with pulmonary hypertension.22 In line with this interpretation, in the present study, 
patients with a PE exhibited a worse right ventricular function, larger right ventricular and 
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right atrial dimensions, more pronounced tricuspid regurgitation as well as a higher 
prevalence of pulmonary hypertension and elevated NT-proBNP, when compared with 
controls. In the subgroup of patients with left and right heart catheterization at baseline, 
patients with PE did indeed exhibit significantly elevated right ventricular filling pressures 
and an increased mean arterial pulmonary pressure, whereas the left ventricular filling 
pressure and wedge pressure did not differ between the PE and the control group. These 
data provide evidence for an important role of the right ventricular function in the 
development of PE in heart failure patients. The transpulmonary gradient was increased in 
the PE group suggesting that a reactive component on top of the left ventricular 
dysfunction might contribute to pulmonary hypertension.23  
The right ventricular and haemodynamic data support and extend the findings of a recent 
study identifying the right ventricular function, right ventricular dimension, and pulmonary 
hypertension as major determinants of functional tricuspid regurgitation,24 but further 
demonstrate an association of such changes with PE. Similar data were demonstrated in 
patients with predominantly preserved LVEF.25 However, the latter study was limited by the 
inclusion of all patients with PE; moreover, detailed echocardiographic data on right 
ventricular function and haemodynamics were not presented. In contrast, a recently 
published study failed to show a  prognostic impact of PE in patients with chronic heart 
failure.26 Unfortunately, only half of the baseline population could finally be included in that 
study. Moreover, the selection of the patients enrolled remained unclear, and may explain 
that in a multivariate analysis PE was not an independent predictor of mortality. Consistent 
with the findings of our study, however, the same authors demonstrated that right atrial and 
right ventricular diameters were increased, ejection fraction was lower, and mortality was 
higher in the PE group. 
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In a subgroup analysis, patients with a resolved PE had a more favourable outcome 
compared with patients with persisting PE indicating improved heart failure treatment and 
recompensation in patients with resolved PE. In contrast, a persistent PE caused by the 
chronic volume overload may identify a patient population at particularly increased risk. 
Numerous systemic or local inflammatory conditions such as rheumatoid diseases,27 myo-
/pericarditis,6 or cancer28 may increase permeability and in turn lead to a capillary leak and 
the development of a PE.29 Of note, severe heart failure goes along with systemic 
inflammation as well.30,31 In the present study, leucocyte counts and C-reactive protein 
levels were increased in patients with PE when compared with those without it, suggesting 
that the systemic inflammation occurring in severe heart failure might induce some 
capillary leakage thereby contributing to pericardial fluid accumulation. Since markers of 
inflammation are associated with a worse outcome also in patients with chronic heart 
failure,32 it cannot be excluded that the presence of PE merely reflects the presence of 
such a systemic inflammatory reaction in these patients. Noteworthy, in the present study, 
64% of patients with PE had a concomitant pleural effusion at baseline. It is well known 
that an elevation of systemic venous pressure and inflammation may affect both 
pericardial and pleural effusions.10   
Haemodynamically non-compromising PE carries a worse prognosis especially in patients 
with heart failure and persistent PE despite heart failure therapy according to current 
guidelines.33 Our findings therefore suggest the need for an intensified surveillance of 
patients in whom PEs are detected. In how far an optimized heart failure treatment, with, 
e.g. implanted devices, to improve fluid management will lead to a reduction in PE and an 
improved outcome in these patients needs to be clarified in a prospective randomized trial. 
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5.2. Limitations 
Observational studies are prone to confounding bias and missing values. Especially, 
biomarker data were available only in a small subset of patients. We have performed 
multivariate adjustments to reduce the confounding but we cannot be sure that there is no 
residual confounding, especially with regard to variables which were not included in the 
model. Moreover, in comparison to the overall study population, the subgroup with PE is 
relatively small which could limit the robustness of the results. A transient appearance of a 
PE between the follow-up visits in some of the patients cannot be excluded. We do report 
on a long recruitment and observation period ranging from 1990 to 2010, but a similar 
number of patients with PE was included before the year 2001 which renders major 
observational biases unlikely; therefore, a potential change in medication and daily clinical 
practice has probably not influenced the results obtained. 
5.3. Conclusion 
In summary, this study suggests that even haemodynamically irrelevant PEs, as detected 
by echocardiography, are associated with adverse outcome. Potential (but speculative) 
mechanisms are right ventricular failure and systemic inflammation due to severe heart 
failure. In how far an optimized heart failure treatment decreases pericardial fluid 
accumulation along with improving survival needs further consideration in a prospective 
trial.  
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6. Tables and figures 
Table 1. Baseline characteristics.  
 No pericardial effusion (n=824 ) 
pericardial 
effusion (n=73 ) p-value 
 Age (years) 55.5 (45.9-64.5) 53.4 (34.4-62.7) 0.05 
 Male (n, %) 675 (82) 53 (73) 0.06 
 BMI (kg/m2) 25.8 (23.4-29.2) 24.7 (21.1-27.0) 0.004 
 Heart rate (bpm) 76.0 (65.0-89.0) 87.0 (76.0-98.0) <0.0001 
 VO2max (ml*kg/min) 19.0 (15.0-25.0) 15.0 (13.0-21.5) 0.15 
 Rhythm (n, %)   0.03 
    Sinus rhythm 601 (81) 41 (66)   
    Atrial fibrillation 95 (13) 14 (23)   
    Pacemaker 46 (6) 7 (11)   
 NYHA class (n,%)   0.01 
     I 49 (9) 2 (4)   
     II 239 (42) 12 (24)   
     III 241 (43) 29 (57)   
     IV 37 (7) 8 (16)   
 Cardiomyopathy (n,%)    
     Dilatative/hypertrophic 311 (38) 45 (62)  
     Non-compaction 16 (2) 0  
     Myocarditis 0 2 (3)  
     Amyloid 2 (0) 0  
     Ischaemic 287 (35) 14 (19)  
     Valvular 53 (6) 4 (6)  
     Congenital 32 (4) 2 (3)  
     Other/unknown 123 (15) 6 (8)  
 Leucocyte count (103/ml) 7.7 (6.1-9.1) 8.4 (7.0-11.3) 0.004 
 C-reactive protein (mg/l) 3.0 (1.0-12.0) 15.0 (4.2-40.3)  <0.0001 
 Platelets (103/ul) 223 (185-272) 223 (182-293) 0.47 
 NT-proBNP (ng/l) 1214 (411-2596) 2240 (1085-5379) 0.01 
 Sodium (mmol/l) 140 (137-141) 139 (137-141) 0.27 
 Haemoglobin (g/dl) 13.8 (12.8-14.9) 13.1 (11.5-14.7) 0.008 
 Creatinine (umol/l) 103 (89-124) 101 (86.8-121) 0.68 
 Diuretics (n, %) 543 (66) 52 (71) 0.44 
 Calciumantagonist (n, %) 58 (7) 10 (14) 0.06 
 Digoxin (n, %) 165 (20) 15 (21) 0.88 
 ACE inhibitor (n, %) 447 (54) 43 (59) 0.46 
 ATII-blocker (n, %) 88 (11) 7 (10) 0.77 
 Spironolactone (n, %) 100 (12) 16 (22) 0.03 
 Statin (n, %) 159 (19) 10 (14) 0.28 
 Beta-Blocker (n, %) 479 (58) 33 (45) 0.04 
 ICD (n, %) 53 (6) 6 (8) 0.47 
 CRT (n, %) 28 (3) 2 (3) 0.76 
 Inclusion before 2001 (n, %) 306 (37) 22 (30) 0.26 
Continous variables are presented as median and interquartile range in brackets, nominal 
variables are presented as number and percentage in brackets.  
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Table 2. Echocardiography baseline parameters. 
  
No pericardial 
effusion (n=824 ) 
pericardial 
effusion (n=73 ) p-value 
 LVEF 34.0 (25.0-47.0) 31.0 (18.0-45.0) 0.04 
 LVESD 4.9 (3.7-5.9) 5.6 (4.0-6.7) 0.01 
 LVEDD 6.2 (5.3-7.0) 6.4 (5.4-7.4) 0.16 
 Mitral regurgitation   0.59 
     minor 200 (32) 15 (25)   
     moderate 296 (48) 28 (47)   
     severe 79 (13) 10 (18)   
 Tricuspid regurgitation   <0.0001 
     minor 347 (57) 19 (31)   
     moderate 202 (34) 27 (44)   
     severe 31 (5) 12 (19)   
 fac (%) 39.0 (33.0-49.0) 33.0 (19.0-42.0) 0.002 
 TAM (mm) 18.0 (15.0-21.0) 14.5 (11.8-20.0) 0.003 
 Right ventricular diameter (cm) 3.2 (2.7-3.6) 3.5 (2.9-4.0) 0.02 
 Right ventricular enddiastolic area (cm2) 18.0 (14.7-22.0) 21.9 (16.0-28.0) 0.001 
 Right atrial diameter long axis (cm) 5.2 (4.7-5.9) 5.9 (4.9-6.5) 0.005 
 Right atrial diameter short axis (cm) 4.1 (3.6-4.6) 4.5 (3.9-5.5) 0.001 
 Left atrial endsystolic diameter (cm) 4.6 (4.0-5.2) 5.0 (4.4-5.8) 0.001 
 Pulmonary pressure elevated 199 (24) 33 (45) 0.03 
Continous variables are presented as median and interquartile range in brackets, nominal 
variables are presented as number and percentage in brackets.  
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Table 3. Follow-up in the study groups.  
  
No pericardial effusion 
(n=824) 
pericardial effusion 
(n=73) p-value 
Follow-up (years) 3.4 (1.1-7.1) 1.8 (0.3-5.5) 0.03 
Death 186 (23) 23 (32)  
   Cardiac death 142 (17) 17 (23)  
   Infection 10 (1) 1 (1)  
   Unknown 13 (2) 2 (3)  
   Cancer  12 (2) 2 (3)  
   Other 9 (1) 1 (1)  
Cancer 33 (4) 5 (7)  
Cardiac death:  
1-year estimator of event free survival 95 ± 1 86 ± 5 0.01 
Heart transplantation 66 (8) 11 (15)  
 
Heart transplantation:  
1-year estimator of event free survival 
94 ± 1 88 ± 4 0.009 
 
Continous variables are presented as median and interquartile range in brackets, nominal 
variabels are presented as number and percentage in brackets.  
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Table 4. Cox proportional hazard model. 
 
Variable Hazard ratio 95% 
confidence intervals 
 
p-value 
Left ventricular ejection fraction < 35% 1.70 1.1 - 2.8 
 
0.03 
Pericardial effusion 1.95 1.0 - 3.7 0.04 
Age (per year) 1.02 1.0 - 1.04 0.04 
Heart rate (per bpm) 1.01 1.0 – 1.03 
 
0.051 
Male gender 0.67 0.37 – 1.2 
 
0.14 
Sinus rhythm vs. atrial fibrillation 0.74 0.35 – 1.5 
 
0.41 
Ischaemic vs. non-ischaemic 
cardiomyopathy  0.77 0.49 – 1.2 0.24 
 
Spironolactone treatment 0.85 0.43 -1.3 0.64 
    
Beta-Blocker treatment 0.84 0.54 – 1.3 0.43 
 
Body-mass-index (kg/m2) 1.01 0.97 – 1.1 0.66 
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Figure 1. Parameters of the right ventricular function and dimension.  
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Figure 2. Left and right ventricular filling pressures at baseline.  
 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Inflammatory parameters and NT-proBNP. 
 
 
 
 
 
 
 
 
 
 
               . 
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Figure 4.  Kaplan-Meier survival analysis of heart failure patients with pericardial 
effusion compared with those without (p = 0.02). 
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